Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zirconium silicate - ZS Pharma

Drug Profile

Zirconium silicate - ZS Pharma

Alternative Names: LOKELMA; Lokelma; Sodium zirconium cyclosilicate; UXSi-9; Ziconite; Zircon; ZS; ZS 9

Latest Information Update: 15 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZS Pharma
  • Developer AstraZeneca; ZS Pharma
  • Class Heavy metals; Minerals; Silicates; Transition elements
  • Mechanism of Action Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperkalaemia

Most Recent Events

  • 22 May 2020 AstraZeneca terminates the phase II PRIORITIZE HF trial in Hyperkalaemia in Hungary, Russia, Brazil, Bulgaria, Canada, Poland, Slovakia, Romania and USA due to COVID-2019 infections (PO) (NCT03532009) (EudraCT2018-000175-33)
  • 04 May 2020 The European Commission approves a dosing and administration label update for zirconium silicate, to include patients with hyperkalaemia on stable haemodialysis
  • 28 Apr 2020 AstraZeneca awaits for final decision on label update from the European Commission in near future
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top